Preventing hypoglycaemia by heavily reducing pre- and post-exercise rapid-acting insulin dose may cause hyperglycaemia, but not hyperketonaemia in type 1 diabetes patients

被引：0
|
作者：
Campbell, M. D. [1 ]
Walker, M. [2 ]
Trenell, M. I. [3 ]
Luzio, S. [4 ]
Dunseath, G. [4 ]
Stevenson, E. J. [1 ]
Bracken, R. M. [5 ]
Turner, D. [5 ]
Bain, S. C. [4 ]
West, D. J. [1 ]
机构：
[1] Northumbria Univ, Dept Sport Exercise & Rehabil, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England
[2] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Swansea Univ, Diabet Res Grp, Swansea, W Glam, Wales
[5] Swansea Univ, Coll Engn, Swansea, W Glam, Wales
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
685
引用
收藏
页码：S277 / S278
页数：2
相关论文
共 39 条
  • [31] COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE
    Levin, Philip
    Fan, Tao
    Song, Xue
    Nero, Damion
    Davis, Brian
    Chu, Bong-Chul
    ENDOCRINE PRACTICE, 2017, 23 (11) : 1316 - 1324
  • [32] Insulin Pump Therapy Is Associated with Less Post-Exercise Hyperglycemia than Multiple Daily Injections: An Observational Study of Physically Active Type 1 Diabetes Patients
    Yardley, Jane E.
    Iscoe, Katherine E.
    Sigal, Ronald J.
    Kenny, Glen P.
    Perkins, Bruce A.
    Riddell, Michael C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 (01) : 84 - 88
  • [33] Intensive replacement of basal insulin on patients with type 1 diabetes given rapid-acting insulin analog at mealtime - A 3-month comparsion between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime
    Rossetti, P
    Pampanelli, S
    Fanelli, C
    Porcellati, F
    Costa, E
    Torlone, E
    Scionti, L
    Bolli, GB
    DIABETES CARE, 2003, 26 (05) : 1490 - 1496
  • [34] Is low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G, an automated insulin delivery system?
    Lundemose, Sissel Banner
    Mccarthy, Olivia M.
    Christensen, Merete Bechmann
    Laugesen, Christian
    Bracken, Richard M.
    Holst, Jens Juul
    Ranjan, Ajenthen Gayathri
    Norgaard, Kirsten
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1164 - 1171
  • [35] Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin in patients with type 2 diabetes: real-world health care costs from a US managed care setting
    Dalal, M.
    Xie, L.
    Baser, O.
    DiGenio, A.
    DIABETOLOGIA, 2013, 56 : S358 - S358
  • [36] Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
    Wysham, Carol H.
    Lin, Jay
    Kuritzky, Louis
    POSTGRADUATE MEDICINE, 2017, 129 (04) : 436 - 445
  • [37] An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial
    Campbell, Matthew D.
    Walker, Mark
    Ajjan, Ramzi A.
    Birch, Karen M.
    Gonzalez, Javier T.
    West, Daniel J.
    DIABETES & VASCULAR DISEASE RESEARCH, 2017, 14 (04): : 336 - 344
  • [38] Combined intake of caffeine and low-dose glucose to reduce exercise-related hypoglycaemia in individuals with type 1 diabetes on ultra-long-acting insulin degludec: A randomized, controlled, double-blind, cross-over trial
    Kuhne, Tobias
    Wallace, Esme
    Herzig, David
    Helleputte, Simon
    Scott, Sam
    Pickles, Jordan
    Melmer, Andreas
    Stettler, Christoph
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2645 - 2651
  • [39] A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes
    Kapitza, Christoph
    Nosek, Leszek
    Schmider, Wolfgang
    Teichert, Lenore
    Mukherjee, Bhaswati
    Nowotny, Irene
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 674 - 681
1234